Christian Weyer is a former CEO of Fate Therapeutics, a company focused on developing cellular therapies. He has a rich background in medicine and research, holding an M.D. from UCLA and significant leadership experience. Before joining Fate, he spent over...

Christian Weyer is a former CEO of Fate Therapeutics, a company focused on developing cellular therapies. He has a rich background in medicine and research, holding an M.D. from UCLA and significant leadership experience. Before joining Fate, he spent over a decade with Amylin Pharmaceuticals, where he ended as Senior Vice President of Research and Development. He was involved in many key projects, helping the company advance its drug pipeline.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Fate Therapeutics CEOs

F

Christian Weyer

Ex-CEO of Fate Therapeutics

Education

M.D. from the University of Ulm, Germany.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

June 15, 1965 - 59 years ago

CEO of Fate Therapeutics for

3 years 2 months (Sep 2012 - Nov 2015)

Previous Experience

Served as Chief Medical Officer at Amylin Pharmaceuticals.

Rivals

Competitors/colleagues of Christian Weyer

Holdings

See how much did Christian Weyer make over time.

During his time at Fate Therapeutics, Christian's stock holdings saw significant fluctuations, reflecting varying performance and market conditions. At their peak, his holdings reportedly reached as high as $29.65 million in early 2021, demonstrating his strong financial stake in the...

During his time at Fate Therapeutics, Christian's stock holdings saw significant fluctuations, reflecting varying performance and market conditions. At their peak, his holdings reportedly reached as high as $29.65 million in early 2021, demonstrating his strong financial stake in the company's success. Over the years, these values dropped to around $1.06 million by September 2024. This swing represents a dramatic change, indicating both the risks involved in the biotech sector and the potential rewards when companies succeed.

Total Stock Sold

$90.32K

FATE

$90.32K

10,000 FATE shares

What if they kept their stock?

If Christian Weyer didn't sell their stock, today they would have:
Extra FATE10,000 shares worth $277.90K.
This is 207.7% and $187.58K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Christian Weyer.

FATE

5,429 shares

FATE

Jan 5, 2015

Received

FATE

$90.18K

FATE at $9.02/share

Apr 1, 2014

Sale

Compensation History

See how much did Christian Weyer make over time.

In 2015, his total compensation was around $707,047, which included a base salary of $366,027. Most of his pay came from stock options valued at $341,020. In contrast, in 2014, his earnings were higher at $965,080, including a significant bonus. The way his pay was structured aligns with company performance, which is common in the biotech industry, emphasizing how executives are rewarded for progress and results rather than just being salaried. He voluntarily stepped down at the end of 2015, leaving a notable financial and leadership imprint on the company.

Year

2015

Total Compensation

$366.03K

Salary

$366.03K

Board Justification

The company aims to align CEO compensation with performance metrics related to corporate objectives, including advancement of clinical and preclinical programs and corporate development initiatives.

Bonus

$0.00

Board Justification

No non-equity incentive plan compensation was reported for 2015 as Dr. Weyer voluntarily resigned before the end of the year.

Other

$0.00

Board Justification

No other compensation was reported for 2015.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards were reported as vested for 2015.

Performance Metrics

The performance metrics for determining compensation included objectives related to the advancement of clinical and preclinical programs and achievement of corporate development and financing initiatives.

Other Fate Therapeutics CEOs

Here are other CEOs of Fate Therapeutics

J. Scott Wolchko

Ex-CEO of Fate Therapeutics

December 2015 - January 2025